Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells

Oncotarget

Volumn 5, Issue 9, 2014, Pages 2622-2634

  Alam, Maroof ^a   Rajabi, Hasan ^a   Ahmad, Rehan ^a,b   Jin, Caining ^c   Kufe, Donald ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c Department of Genus Oncology   (United States)

Author keywords

Breast cancer; Mammospheres; MUC1; NF B; Stem like cells; Tumorigenicity

Indexed keywords

CELL PENETRATING PEPTIDE; CHEMOKINE RECEPTOR CXCR1; GO 203; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; MUCIN 1C; ONCOPROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; (ARGININE)9-CYSTEINYL-GLUTAMINYL-CYSTEINYL-ARGINYL-ARGINYL-LYSYL-ASPARAGINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MESSENGER RNA; MUC1 PROTEIN, HUMAN; MUCIN 1; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL RENEWAL; CONTROLLED STUDY; DRUG TARGETING; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSCRIPTION INITIATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT; AMINO ACID SEQUENCE; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CELL PROLIFERATION; CHEMISTRY; CHROMATIN IMMUNOPRECIPITATION; DRUG EFFECTS; DRUG SCREENING; GENETICS; IMMUNOPRECIPITATION; METABOLISM; MOLECULAR GENETICS; MULTICELLULAR SPHEROID; NUDE MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; FEMALE; HUMANS; IMMUNOPRECIPITATION; INTERLEUKIN-8; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR SEQUENCE DATA; MUCIN-1; NF-KAPPA B; PEPTIDES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901235589     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1848     Document Type: Article

References (55)

1. Reya T, Morrison SJ, Clarke MF and Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001; 414:105-111.
2. Shackleton M, Quintana E, Fearon ER and Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell. 2009; 138:822-829.
3. Visvader JE and Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008; 8:755-768.
4. Magee JA, Piskounova E and Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell. 2012; 21:283-296.
5. Visvader JE and Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell. 2012; 10:717-728.
6. Ma I and Allan AL. The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev. 2011; 7:292-306.
7. Singh A and Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010; 29:4741-4751.
8. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133:704-715.
9. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ and Wicha MS. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003; 17:1253-1270.
10. Liao MJ, Zhang CC, Zhou B, Zimonjic DB, Mani SA, Kaba M, Gifford A, Reinhardt F, Popescu NC, Guo W, Eaton EN, Lodish HF and Weinberg RA. Enrichment of a population of mammary gland cells that form mammospheres and have in vivo repopulating activity. Cancer Res. 2007; 67:8131-8138.
11. Cao Y, Luo JL and Karin M. IkappaB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells. Proc Natl Acad Sci USA. 2007; 104:15852-15857.
12. Shostak K and Chariot A. NF-kappaB, stem cells and breast cancer: the links get stronger. Breast Cancer Res. 2011; 13:214.
13. Kendellen MF, Bradford JW, Lawrence CL, Clark KS and Baldwin AS. Canonical and non-canonical NF-kappaB signaling promotes breast cancer tumor-initiating cells. Oncogene. 2013:[Epub ahead of print].
14. Todorovic-Rakovic N and Milovanovic J. Interleukin-8 in breast cancer progression. J Interferon Cytokine Res. 2013.
15. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009; 69:1302-1313.
16. Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M, Wicinski J, Cabaud O, Charafe-Jauffret E, Birnbaum D, Guan JL, Dontu G and Wicha MS. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest. 2010; 120:485-497.
17. Fernando RI, Castillo MD, Litzinger M, Hamilton DH and Palena C. IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Res. 2011; 71:5296-5306.
18. Singh JK, Farnie G, Bundred NJ, Simoes BM, Shergill A, Landberg G, Howell SJ and Clarke RB. Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms. Clin Cancer Res. 2013; 19:643-656.
19. Kufe D. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene 2013; 32:1073-1081.
20. Raina D, Uchida Y, Kharbanda A, Rajabi H, Panchamoorthy G, Jin C, Kharbanda S, Scaltriti M, Baselga J and Kufe D. Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells. Oncogene. 2013:[Epub ahead of print].
21. Raina D, Kosugi M, Ahmad R, Panchamoorthy G, Rajabi H, Alam M, Shimamura T, Shapiro G, Supko J, Kharbanda S and Kufe D. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Therapeutics. 2011; 10:806-816.
22. Raina D, Ahmad R, Rajabi H, Panchamoorthy G, Kharbanda S and Kufe D. Targeting cysteine-mediated dimerization of the MUC1-C oncoprotein in human cancer cells. Int J Oncol. 2012; 40:1643-1649.
23. Alam M, Ahmad R, Rajabi H, Kharbanda A and Kufe D. MUC1-C oncoprotein activates ERK→C/EBPß-mediated induction of aldehyde dehydrogenase activity in breast cancer cells. J Biol Chem. 2013; 288:30829-30903.
24. Ahmad R, Raina D, Joshi MD, Kawano T, Kharbanda S and Kufe D. MUC1-C oncoprotein functions as a direct activator of the NF-κB p65 transcription factor. Cancer Res. 2009; 69:7013-7021.
25. Rajabi H, Alam M, Takahashi H, Kharbanda A, Guha M, Ahmad R and D. K. MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition. Oncogene. 2013 Apr 15 [Epub ahead of print].
26. Engelmann K, Shen H and Finn OJ. MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1. Cancer Res. 2008; 68:2419-2426.
27. Ren J, Agata N, Chen D, Li Y, Yu W-H, Huang L, Raina D, Chen W, Kharbanda S and Kufe D. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anti-cancer agents. Cancer Cell. 2004; 5:163-175.
28. Morrison BJ, Hastie ML, Grewal YS, Bruce ZC, Schmidt C, Reynolds BA, Gorman JJ and Lopez JA. Proteomic comparison of mcf-7 tumoursphere and monolayer cultures. PloS One. 2012; 7:e52692.
29. Grimshaw MJ, Cooper L, Papazisis K, Coleman JA, Bohnenkamp HR, Chiapero-Stanke L, Taylor-Papadimitriou J and Burchell JM. Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells. Breast Cancer Res. 2008; 10:R52.
30. Guttilla IK, Phoenix KN, Hong X, Tirnauer JS, Claffey KP and White BA. Prolonged mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs. Breast Cancer Res Treat. 2012; 132:75-85.
31. Ahmad R, Raina D, Trivedi V, Ren J, Rajabi H, Kharbanda S and Kufe D. MUC1 oncoprotein activates the IκB kinase ß complex and constitutive NF-κB signaling. Nat Cell Biol. 2007; 9:1419-1427.
32. Korkaya H, Liu S and Wicha MS. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest. 2011; 121:3804-3809.
33. Chin AR and Wang SE. Cytokines driving breast cancer stemness. Mol Cell Endocrinol. 2014; 382:598-602.
34. Hinohara K, Kobayashi S, Kanauchi H, Shimizu S, Nishioka K, Tsuji E, Tada K, Umezawa K, Mori M, Ogawa T, Inoue J, Tojo A and Gotoh N. ErbB receptor tyrosine kinase/NF-kappaB signaling controls mammosphere formation in human breast cancer. Proc Natl Acad Sci USA. 2012; 109:6584-6589.
35. Singh JK, Simoes BM, Howell SJ, Farnie G and Clarke RB. Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res. 2013; 15:210.
36. Maxwell PJ, Gallagher R, Seaton A, Wilson C, Scullin P, Pettigrew J, Stratford IJ, Williams KJ, Johnston PG and Waugh DJ. HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene. 2007; 26:7333-7345.
37. Siroy A, Abdul-Karim FW, Miedler J, Fong N, Fu P, Gilmore H and Baar J. MUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer. Hum Pathol. 2013; 44:2159-66.
38. Wei X, Xu H and Kufe D. MUC1 oncoprotein stabilizes and activates estrogen receptor a. Mol Cell. 2006; 21:295-305.
39. Pitroda S, Khodarev N, Beckett M, Kufe D and Weichselbaum R. MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment. Proc Natl Acad Sci USA 2009; 106:5837-5841.
40. Kharbanda A, Rajabi H, Jin C, Raina D and Kufe D. MUC1-C oncoprotein induces tamoxifen resistance in human breast cancer. Mol Cancer Res. 2013; 11:714-723.
41. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007; 1:555-567.
42. Freund A, Jolivel V, Durand S, Kersual N, Chalbos D, Chavey C, Vignon F and Lazennec G. Mechanisms underlying differential expression of interleukin-8 in breast cancer cells. Oncogene. 2004; 23:6105-6114.
43. Hartman Z, Poage G, den Hollander P, Tsimelzon A, Hill J, Panupinthu N, Zhang Y, Mazumdar A, Hilsenbeck S, Mills G and Brown P. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the pro-inflammatory cytokines IL-6 and IL-8. Can Res. 2013; 73:3470-3480.
44. Stein B and Baldwin AS, Jr. Distinct mechanisms for regulation of the interleukin-8 gene involve synergism and cooperativity between C/EBP and NF-kappa B. Mol Cell Biol. 1993; 13:7191-7198.
45. LaMarca HL, Visbal AP, Creighton CJ, Liu H, Zhang Y, Behbod F and Rosen JM. CCAAT/enhancer binding protein beta regulates stem cell activity and specifies luminal cell fate in the mammary gland. Stem Cells. 2010; 28:535-544.
46. Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, Ceccarelli C, Santini D, Paterini P, Marcu KB, Chieco P and Bonafe M. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest. 2007; 117:3988-4002.
47. Korkaya H, Paulson A, Iovino F and Wicha MS. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene. 2008; 27:6120-6130.
48. Korkaya H, Paulson A, Charafe-Jauffret E, Ginestier C, Brown M, Dutcher J, Clouthier SG and Wicha MS. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Bio. 2009; 7:e1000121.
49. Raina D, Ahmad R, Joshi M, Yin L, Wu Z, Kawano T, Vasir B, Avigan D, Kharbanda S and Kufe D. Direct targeting of the MUC1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res. 2009; 69:5133-5141.
50. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, Joshua B, Kaplan MJ, Wapnir I, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009; 458:780-783.
51. Cui X. Reactive oxygen species: the achilles' heel of cancer cells? Antioxid Redox Signal. 2012; 16:1212-1214.
52. Kobayashi CI and Suda T. Regulation of reactive oxygen species in stem cells and cancer stem cells. J Cell Physiol. 2012; 227:421-430.
53. Gorrini C, Harris IS and Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013; 12:931-947.
54. Uchida Y, Raina D, Kharbanda S and Kufe D. Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in treatment of breast cancer cells. Cancer Biol Ther. 2013; 14:127-134.
55. Wang Q, Carroll JS and Brown M. Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell. 2005; 19:631-642.